Loading patent…
OwnerTerry W. Du Clos, Carolyn Moldinventors
Estimating the term…
The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE. The present invention also relates to the treatment of immune thrombocytopenic purpura. Pharmaceutical compositions are also disclosed based these mutant CRP molecules.
A method of treating, inhibiting or reducing the likelihood of systemic lupus erythematosus (SLE) or a secondary disease state, condition or manifestation associated with SLE or immune thrombocytopenic purpura in a patient comprising administering to said patient an effective amount of at least one compound selected from the group consisting of Y175L CRP and L176E CRP, in combination with a carrier, additive or excipient and optionally in combination with a natural or synthetic active carrier.
(canceled)
A pharmaceutical composition comprising an effective amount of CRP mutant polypeptide selected from the group consisting of Y175L CRP, L176E CRP or mixtures thereof, in combination with a pharmaceutically acceptable carrier, additive or excipient and optionally in combination with an active carrier.
26-36. (canceled)
Dependencies are inferred from the claim text.